Skip to main content
. 2020 Jan 6;11(1):18. doi: 10.1038/s41419-019-2204-y

Fig. 2. miR-578 targets VEGF in osteosarcoma.

Fig. 2

a Prediction of putative-binding sites between miR-578 and VEGF by miRDB. b Negative correlation between miR-578 expression and VEGF. c Luciferase reporter assay indicated that VEGF DEL abrogated the inhibition of VEGF promoter activity. **P < 0.01, vs control. d–g VEGF expression in cells expressing control, miR-578 or miR-578 inhibitor was detected by western blot and real-time PCR, respectively. Results represented the mean ± s.d. of three independent experiments. **P < 0.01, vs control. miR-578 in, miR-578 inhibitor.